Efficacy of Prednisolone and Losartan Potassium in Post-Acute COVID-19 Inflammatory Cardiovascular Involvement: A Randomized, Placebo-Controlled Trial
- Trial ID
- 2024-516463-84-00
- Protocol
- MYOFLAME-19
- Sponsor
- Goethe University Frankfurt
Register record, history and transparency: CTIS.eu
Trial statistics
Diseases & Conditions
Objectives
The primary objective of this study is to evaluate the **efficacy** of a combined immunosuppressive and antiremodelling therapy in reducing inflammatory myocardial injury in patients with COVID-19 related inflammatory cardiovascular involvement, as assessed by cardiovascular magnetic resonance (CMR) imaging, compared to placebo. Additionally, the primary safety objective is to confirm the safety of the proposed doses of this combined therapy in the specified patient population.
The secondary objectives aim to assess the efficacy of the combined therapy in improving other clinical parameters related to COVID-19 induced inflammatory cardiovascular involvement, as measured by CMR, compared to placebo.
Participants
The clinical trial involves a study population comprising both **male** and **female** participants aged 18 years and older. The participants are individuals with documented recent COVID-19 infection, specifically those experiencing post-acute sequelae of SARS-CoV-2 infection (PASC) syndrome. The trial focuses on individuals with **inflammatory cardiovascular involvement** as evidenced by cardiovascular magnetic resonance imaging (CMR). The study population includes a vulnerable group, and participants are required to demonstrate willingness to comply with study procedures and protocols. The sponsor has not provided information regarding the total number of participants. Key lifestyle considerations such as diet, physical activity, or habits are not specified in the available data.
Plans and Procedures
The clinical trial is designed as a **randomized**, **double-blind**, placebo-controlled study to evaluate the efficacy and safety of a combined immunosuppressive and antiremodelling therapy in patients with inflammatory cardiovascular involvement due to COVID-19. The trial aims to assess the reduction of inflammatory myocardial injury using cardiovascular magnetic resonance imaging (CMR) as the primary endpoint. The study will involve participants aged 18 years and older who have documented recent COVID-19 infection and evidence of inflammatory cardiac involvement as determined by CMR. The trial is expected to commence recruitment on September 1, 2024, and conclude by June 30, 2026.
Participants will be involved in the study for a maximum treatment period of 16 weeks. The trial will include several key visits: an initial screening visit to confirm eligibility, baseline assessments, and subsequent follow-up visits at regular intervals to monitor treatment effects and safety. The end-of-study visit will occur at week 16, where the primary endpoint of absolute change in left ventricular ejection fraction (LVEF) will be measured. Secondary endpoints will include changes in late gadolinium enhancement, cardiopulmonary exercise testing parameters, and myocardial strain, among others.
Participants will be randomly assigned to receive either the active treatment or a placebo, with the active treatment consisting of **prednisolone** and **losartan potassium**. The placebo will be composed of Füllstoff DAC in hard gelatine capsules. The study will employ over-encapsulation of tablets to maintain blinding. Participants may be withdrawn from the study early if they experience significant adverse effects, require dose reduction, or if unblinding is necessary due to emergency safety issues. Compliance and tolerance will be closely monitored throughout the trial, with adherence to prescribed medication and any necessary dose adjustments documented.
Treatment
The clinical trial involves the administration of several treatments, including both experimental and non-experimental medications. **Prednisolone** is utilized in two different dosages: 10 mg and 5 mg, both provided by MIBE GMBH ARZNEIMITTEL. The pharmaceutical form of these medications is a tablet, and they are administered orally. The maximum daily dose for each is 20 mg, with a total treatment period of up to 16 weeks. The tablets have been modified by over-encapsulation to ensure blinding during the trial.
**Losartan Potassium** is another experimental medication used in the trial, available in two dosages: 12.5 mg and 25 mg. The 12.5 mg dosage is provided by TAD PHARMA GMBH, while the 25 mg dosage is supplied by 123 ACURAE PHARMA GMBH. Both are in the form of film-coated tablets and are administered orally. The maximum daily dose for Losartan Potassium is 50 mg, with a treatment duration of up to 16 weeks. Similar to Prednisolone, these tablets are also over-encapsulated for blinding purposes.
The non-experimental treatment in this study is a placebo, known as Füllstoff DAC, which is encapsulated in hard gelatine capsules. The placebo consists of 99.5% mannitol and 0.5% colloidal silicon dioxide. The placebo is administered orally, following the same schedule as the experimental medications, to maintain the integrity of the double-blind study design.
Participant compliance with the dosing schedule is monitored throughout the trial to ensure adherence to the treatment protocol. The trial aims to evaluate the efficacy and safety of the combined immunosuppressive and antiremodelling therapy in reducing inflammatory myocardial injury in patients with COVID-19 related inflammatory cardiovascular involvement.
Efficacy
The efficacy of the clinical trial titled "Randomised placebo controlled clinical trial of efficacy of MYOcardial protection in postacute inFLAMmatory cardiac involvEment due to COVID-19 (MYOFLAME-19)" will be assessed using specific primary and secondary endpoints. The primary endpoint is the absolute change in Left Ventricular Ejection Fraction (LVEF) from baseline to week 16, measured by Cardiovascular Magnetic Resonance (CMR), and compared between the treatment and placebo groups by absolute treatment difference.
Secondary endpoints include a range of continuous measures, with changes referring to the difference between baseline and week 16. These include the mean extent of Late Gadolinium Enhancement (LGE) and its change, Cardiopulmonary Exercise Testing (CPET) parameters such as achieved Work Rate, VO2max, VCO2 max, Respiratory Exchange Ratio (RER), Anaerobic Threshold (AT), and slope, as well as mean T1 and T2 values. Additional secondary endpoints involve mean Left Ventricular (LV) and Right Ventricular (RV) volumes, LV mass, myocardial strain, pulse wave velocity, aortic wall thickness, and average symptom score, all assessed for changes from baseline. Compliance and tolerance will also be evaluated, including medication adherence and the number of participants requiring dose adjustments due to side effects.
Furthermore, the trial will assess the number of responders achieving partial or total response, defined by normal CMR results and absence of LGE, respectively. Long-term outcomes such as the proportion of participants with heart failure or major adverse cardiovascular events (MACE) after one year, and one-year event-free survival, will also be considered. These efficacy parameters will be collected and analyzed at specified timepoints, primarily at baseline and week 16, using validated tools and methodologies appropriate for each measure.
Inclusion and Exclusion Criteria
Inclusion Criteria
- Participants ≥ 18 years
- Participants with documented recent COVID19 infection (> 4 weeks)
- Post-acute sequelae of SARS-CoV-2 infection (PASC) Syndrome, defined by persistence or new symptoms, not present prior to the infection.
- Cardiovascular magnetic resonance imaging (CMR) evidence of inflammatory cardiac involvement at baseline (BL) by any of the following criteria: o Increased native T1≥ 1130 ms at 3.0 Tesla (or 1030 ms at 1.5 Tesla) and/or; o Increased native T2 ≥39.5 ms at 3.0 Tesla (or 49.5 at 1.5 Tesla)and/or o present non-ischaemic myopericardial Late gadolinium enhancement (LGE) and/or; o Left ventricular ejection fraction (LVEF) ≥45 - ≤50%.
- Willingness to comply with the study procedures and study protocol.
Exclusion Criteria
- Severe course of acute COVID illness requiring hospitalisation
- Participants currently participating in an investigational study or for whom participation is planned.
- Unable to provide written informed consent
- Known allergy to or intolerance of the study medications
- Symptomatic hypotension (systolic blood pressure less than 90 mm Hg), not reversible with oral hydration
- Any previous or current use of ACE inhibitors, AR Blockers
- Any previous oral prednisolone, or any other immunosuppressive or biological treatment (within prior 10 weeks)
- History or CMR evidence of preexisting heart disease, including: a. Known cardiac impairment with LVEF ≤44% b. Congestive heart failure (NYHA III-IV) c. Active heart failure treatment d. Established ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease e. Persistent or permanent atrial fibrillation or significant heart rhythm abnormalities. f. Congenital or clinically relevant valvular heart disease (moderate or severe) g. Specific cardiomyopathy (hypertrophic, hypertensive heart disease, amyloidosis, previous myocarditis, non-ischaemic dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, noncompaction cardiomyopathy, etc).
- Known significant concomitant diseases that are likely to interfere with the evaluation of the participant’s safety and of the study outcome (e.g. diabetes, lung or hepatic disease, epilepsy, psychiatric disorders, renal disease with a current estimated GFR <30 mL/min/1.73 m² using MDRD formula, chronic systemic infection or immunocompromise)
- Exceeding scanner bore and table-holding capacity: Weight >125 kg, BMI > 35 kg/m2
- Contraindications to contrast-enhanced CMR imaging, e.g. a. MR-unsafe implantable device b. known allergy to gadolinium-based contrast agent (CBGA)
- For female participants: a. Pregnant or breastfeeding women b. Women of childbearing potential not willing to use highly effective contraception (as defined in 18.2.13)
- Known alcohol, drug or chemical abuse
- Participants currently participating in an investigational study or for whom participation is planned.
- Unable to provide written informed consent.
- Participants with CMR evidence of structural heart disease or incidental heart rhythm abnormalities will be advised to see their own doctor for further investigation.
Trial Status by Country
| Country | Status | Start of Recruitment | Planned Patients |
|---|---|---|---|
Austria | Not Recruiting | 01 Sept 2024 | 20 |
Germany | Not Recruiting | 01 Sept 2024 | 260 |
Sites & Investigators
Investigational Products
Details about the medicinal products being studied in this clinical trial.
| Product Name | Role in Trial | Formulation | Administration | Max Daily Dose | Treatment Duration | EU MP Number |
|---|---|---|---|---|---|---|
Prednisolon 5 mg JENAPHARM | Test | TABLET | ORAL USE | 20 | 16 | PRD1752711 |
Losartan-Kalium TAD® 25 mg Filmtabletten
Wirkstoff: Losartan-Kalium | Test | FILMTABLETTEN | ORAL USE | 50 | 16 | PRD11267843 |
Prednisolon 10 mg JENAPHARM | Test | TABLET | ORAL USE | 20 | 16 | PRD1752709 |
Füllstoff DAC in hard gelatine capsules is used as placebo. Füllstoff DAC consists of mannitol 99.5 % and colloidal Silicon Dioxide 0.5 % | Placebo | N/A | — | — | — | N/A |
Losartan-Kalium TAD 12,5 mg Filmtabletten | Test | FILMTABLETTEN | ORAL USE | 50 | 16 | PRD449861 |


